1. People

Mark Burkard, MD, PhD

Professor of Internal Medicine-Hematology, Oncology, and Blood and Marrow Transplantation

Current Positions

  • Professor of Internal Medicine-Hematology, Oncology, and Blood and Marrow Transplantation
  • Director, University of Iowa Health Care Holden Comprehensive Cancer Center

Education

  • BS in Mathematical Physics, State University of New York at Buffalo, Buffalo, NY
  • PhD in Chemistry, University of Rochester, Rochester, New York
  • MD, School of Medicine and Dentistry, University of Rochester, Rochester, New York
  • Residency, Internal Medicine, Medical Research Pathway, New York Presbyterian Hospital, Cornell Campus, New York, NY
  • Fellowship, Medial Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

Center, Program and Institute Affiliations

Licenses & Certifications

  • Certification, American Board of Internal Medicine
  • Certification, American Board of Internal Medicine, Medical Oncology

Selected Publications

  • Li BT, Gandhi L, Ravichandran V, Besse B, Mazieres J, Shapiro G, Boni V, Waqar SN, Park H, Quinn DI, Martinez A, Stemmer SM, Cortot AB, Barlesi F, Quoix E, Burkard ME, Won H, Selcuklu D, Savin C, Donaghue MTA, Kris MG, Bebchuk J, Eli LD, McCulloch L, Solit DB, Janne PA. Efficacy of neratinib-based therapy in HER2-mutant lung adenocarcinomas: findings from two international phase 2 studies. doi: 10.1016/j.jtho.2021.01.158
  • Okines A, Curigliano G, Mizuno N, Oh D-Y, Rorive A, Soliman H, Takahashi S, Bekaii-Saab T, Burkard ME Chung K, Debruyne P, Fox J, Gambardella V, Gil Martin M, Hamilton E, Monk BJ, Nakamura Y, Nguyen D, O’Malley DM, Olawaiye A, Pothuri B, Reck M, Sudo K, Sunakawa Y, Van Marcke C, Yu EY, Ramos J, Tan S, Bieda M, Stinchcombe TE, Pohlmann P. Tucatinib and trastuzumab for previously treated HER2-mutated/metastatic breast cancer (SGNTUC-019): A phase 2 basket trial. Nat Med 31, 909–916 (2025). https://doi.org/10.1038/s41591-024-03462-0
  • Norman RX, Chen YC, Recchia EE, Loi J, Rosemarie Q, Lesko SL, Patel S, Sherer N, Takaku M, Burkard ME, Suzuki A. One step 4x and 12x 3D-ExM: robust super-resolution microscopy in cell biology. bioRxiv [Preprint]. 2024 Aug 13:2024.08.13.607782. doi: 10.1101/2024.08.13.607782. Update in: J Cell Biol. 2025 Feb 3;224(2):e202407116. doi: 10.1083/jcb.202407116. PMID: 39185153; PMCID: PMC11343106.
  • Tucker JB, Carlsen CL, Scribano CM, Pattaswamy SM, Burkard ME, Weaver BA. CENP-E Inhibition Induces Chromosomal Instability and Synergizes with Diverse Microtubule-Targeting Agents in Breast Cancer. Cancer Res. 2024 Aug 15;84(16):2674-2689. doi: 10.1158/0008-5472.CAN-23-3332. PMID: 38832939; PMCID: PMC11326998.
  • Horn IP, Zakas AL, Smith-Simmer KJ, Birkeland LE, Sundstrom R, Burkard ME, Weiss JM. Genetic Testing Utilization: Discrepancies Between Somatic and Germline Results in Patients With Cancer Reviewed at the UW Health Precision Medicine Molecular Tumor Board. JCO Precis Oncol. 2024 May;8:e2300466. doi: 10.1200/PO.23.00466. PMID: 38810171.
  • Lynch A, Bradford S, Burkard ME. The reckoning of chromosomal instability: past, present, future. Chromosome Res. 2024 Feb 17;32(1):2. doi: 10.1007/s10577-024-09746-y. PMID: 38367036.
  • Loeser A, Kim JS, Peppercorn J, Burkard ME, Niemierko A, Juric D, Kalinsky K, Rugo H, Glenn L, Hodgdon C, Maues J, Johnson S, Padron N, Parekh K, Lustberg M, Bardia A. The Right Dose: Results of a Patient Advocate-Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life. JCO Oncol Pract. 2024 Jul;20(7):972-983. doi: 10.1200/OP.23.00539. Epub 2024 Mar 22. PMID: 38518184.
  • Xu W, Gao A, Khatri P, Ma G, Donahue K, Wang Y, Kim E-J, Hu M, Liu F, Schwartz R, Ong I, Burkard ME, Wisinski K, Dinh H. BRD8 is a therapeutic vulnerability for overcoming resistance to dual ER/HER2 blockade therapy in HR+/HER2+ breast cancer. Submitted.
  • Zhou AS, Tucker JB, Scribano CM, Lynch AR, Carlsen CL, Pop-Vicas ST, Pattaswamy SM, Burkard ME, Weaver BA. Diverse microtubule-targeted anticancer agents kill cells by inducing chromosome missegregation on multipolar spindles. PLoS Biol. 2023 Oct 26;21(10):e3002339. doi: 10.1371/journal.pbio.3002339. Erratum in: PLoS Biol. 2025 Feb 12;23(2):e3003039. doi: 10.1371/journal.pbio.3003039. PMID: 37883329; PMCID: PMC10602348.

People